News | June 18, 2022
Aether Industries Q4 FY22 revenue up 26.8%; Profit up 13.8%
Revenues from operations for the full year ended March 31, 2022 stood at Rs. 590.05 crore as compared to Rs. 449.82 crore in FY21
Revenues from operations for the full year ended March 31, 2022 stood at Rs. 590.05 crore as compared to Rs. 449.82 crore in FY21
48% of people are either hypertensive or at risk of becoming hypertensive & 30% of people have a high Waist Hip Ratio (WHR) – an early indication of the onset of CVDs
First and only FDA-approved device of its kind demonstrates consistently high rates of target limb salvage and freedom from clinically-driven target lesion revascularization
Tislelizumab is now approved in nine indications in China
Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood
A big boost to healthcare efforts of Ayush through NARIP, CCRAS
If approved, Tafinlar + Mekinist may offer a potential new standard-of-care for pediatric patients with this brain cancer
Scemblix (asciminib) continues to show superior efficacy with more-than-two-fold improvement in major molecular response rate vs. Bosulif (bosutinib) at 96 weeks
Immune-mediated events and infusion reactions were higher with KEYTRUDA (38% vs 9%, respectively).
C2i Genomics expands its global reach and brings the first whole-genome sequencing minimal residual disease test to India
Subscribe To Our Newsletter & Stay Updated
